Heterologous Immunization Targeting the CST1 Antigen Confers Better Protection Than ROP18 in Mice

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2024 Sep 25

PMID 39320318

Authors

Gi-Deok Eom

Ki Back Chu

Jie Mao

Keon-Woong Yoon

Hae-Ji Kang

Eun-Kyung Moon

Sung Soo Kim

Fu-Shi Quan

Affiliations

Soon will be listed here.

Abstract

To evaluate the protective efficacy induced by heterologous immunization with recombinant baculoviruses or virus-like particles targeting the CST1 and ROP18 antigens of .: Recombinant baculovirus and virus-like particle vaccines expressing CST1 or ROP18 antigens were developed to evaluate protective immunity in mice upon challenge infection with 450 (ME49). Immunization with CST1 or ROP18 vaccines induced similar levels of -specific IgG and IgA responses. Compared with ROP 18, CST1 vaccine showed better antibody-secreting cell response, germinal center B cell activation, and significantly reduced brain cyst burden and body weight loss. Our findings suggest that CST1 heterologous immunization elicited better protection than ROP18, providing important insight into improving the toxoplasmosis vaccine design strategy.

References

Lee S, Kang H, Lee D, Kang S, Quan F . Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection. Vaccine. 2018; 36(38):5692-5700. DOI: 10.1016/j.vaccine.2018.08.016. View

Tomita T, Bzik D, Ma Y, Fox B, Markillie L, Taylor R . The Toxoplasma gondii cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence. PLoS Pathog. 2014; 9(12):e1003823. PMC: 3873430. DOI: 10.1371/journal.ppat.1003823. View

McCabe R, Luft B, Remington J . Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis. 1984; 150(6):961-2. DOI: 10.1093/infdis/150.6.961. View

Mizutani M, Iyori M, Blagborough A, Fukumoto S, Funatsu T, Sinden R . Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect Immun. 2014; 82(10):4348-57. PMC: 4187867. DOI: 10.1128/IAI.02040-14. View

Robert-Gangneux F, Darde M . Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012; 25(2):264-96. PMC: 3346298. DOI: 10.1128/CMR.05013-11. View

Dubremetz J . Rhoptries are major players in Toxoplasma gondii invasion and host cell interaction. Cell Microbiol. 2007; 9(4):841-8. DOI: 10.1111/j.1462-5822.2007.00909.x. View

Bergersen K, Barnes A, Worth D, David C, Wilson E . Targeted Transcriptomic Analysis of C57BL/6 and BALB/c Mice During Progressive Chronic Infection Reveals Changes in Host and Parasite Gene Expression Relating to Neuropathology and Resolution. Front Cell Infect Microbiol. 2021; 11:645778. PMC: 8012756. DOI: 10.3389/fcimb.2021.645778. View

Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A . Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. Acta Trop. 2014; 137:185-94. DOI: 10.1016/j.actatropica.2014.05.015. View

Yoon K, Chu K, Kang H, Kim M, Eom G, Mao J . Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles Expressing Rhoptry Protein 18. Vaccines (Basel). 2022; 10(10). PMC: 9609909. DOI: 10.3390/vaccines10101588. View

10.

Yu L, Yamagishi J, Zhang S, Jin C, Aboge G, Zhang H . Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. Parasitol Int. 2012; 61(3):481-6. DOI: 10.1016/j.parint.2012.04.001. View

11.

Quan F, Vunnava A, Compans R, Kang S . Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010; 5(2):e9161. PMC: 2820088. DOI: 10.1371/journal.pone.0009161. View

12.

Chatterjee A, Banerjee S, Steffen M, OConnor R, Ward H, Robbins P . Evidence for mucin-like glycoproteins that tether sporozoites of Cryptosporidium parvum to the inner surface of the oocyst wall. Eukaryot Cell. 2009; 9(1):84-96. PMC: 2805294. DOI: 10.1128/EC.00288-09. View

13.

Hamilton C, Black L, Oliveira S, Burrells A, Bartley P, Melo R . Comparative virulence of Caribbean, Brazilian and European isolates of Toxoplasma gondii. Parasit Vectors. 2019; 12(1):104. PMC: 6416883. DOI: 10.1186/s13071-019-3372-4. View

14.

Masip Y, Caeiro L, Cosenza M, Postan M, Molina G, Taboga O . Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic infection. Front Cell Infect Microbiol. 2024; 14:1297321. PMC: 10933115. DOI: 10.3389/fcimb.2024.1297321. View

15.

Sullivan Jr W, Jeffers V . Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol Rev. 2011; 36(3):717-33. PMC: 3319474. DOI: 10.1111/j.1574-6976.2011.00305.x. View

16.

Faridnia R, Daryani A, Sarvi S, Sharif M, Kalani H . Vaccination against Toxoplasma gondii using rhoptry antigens: a systematic review. Comp Immunol Microbiol Infect Dis. 2018; 59:32-40. DOI: 10.1016/j.cimid.2018.09.005. View

17.

Barnes D, Bonnin A, Huang J, Gousset L, Wu J, Gut J . A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion. Mol Biochem Parasitol. 1998; 96(1-2):93-110. DOI: 10.1016/s0166-6851(98)00119-4. View

18.

Hiszczynska-Sawicka E, Gatkowska J, Grzybowski M, Dlugonska H . Veterinary vaccines against toxoplasmosis. Parasitology. 2014; 141(11):1365-78. DOI: 10.1017/S0031182014000481. View

19.

Weiss L, Laplace D, Takvorian P, Tanowitz H, Cali A, Wittner M . A cell culture system for study of the development of Toxoplasma gondii bradyzoites. J Eukaryot Microbiol. 1995; 42(2):150-7. DOI: 10.1111/j.1550-7408.1995.tb01556.x. View

20.

Eom G, Chu K, Kang H, Kim M, Yoon K, Mao J . Protective mucosal and systemic immunity induced by virus-like particles expressing Toxoplasma gondii cyst wall protein. PLoS One. 2023; 18(4):e0283928. PMC: 10138198. DOI: 10.1371/journal.pone.0283928. View